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Abstract A 750-bp fragment of a novel human cysteine 
protease has been identified from the dbEST databank. PCR 
cloning and DNA sequencing yielded a 1.38-kb full-length cDNA 
which encodes a polypeptide of 376 amino acids. The protein 
consists of a putative 21-residue signal peptide, a 106-residue 
propeptide and a 252-residue mature protein. The deduced amino 
acid sequence contains the highly conserved residues of the 
catalytic triad of papain-like cysteine proteases: cysteine, 
histidine, and asparagine. Furthermore, the protein sequence 
possesses two potential ./V-glycosylation sites: one in the 
propeptide and one in the mature protein. Comparison of the 
amino acid sequence of human cathepsin W with other human 
thiol-dependent cathepsins revealed a relatively low degree of 
similarity (21-31%). In contrast to cathepsins L, S, K, B, H and 
O, cathepsin W contains a 21-amino acid peptide insertion 
between the putative active site histidine and asparagine residues 
and an 8-amino acid C-terminal extension. This unique sequence 
may indicate that cathepsin W belongs in a novel subgroup of 
papain-like proteases distinct from that of cathepsin L- and B-
like proteases. Northern blot analysis indicates a specific 
expression of cathepsin W in lymphatic tissues. Further analysis 
revealed predominant levels of expression in T-lymphocytes, and 
more specifically in CD8+ cells. The expression of the protease in 
cytotoxic T-lymphocytes may suggest a specific function in the 
mechanism or regulation of T-cell cytolytic activity. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Lysosomal cysteine proteases such as the cathepsins B, L, H 
and C play an important role in intracellular protein turnover. 
This function, and the proteases' ubiquitous tissue distribu-
tion may reflect a 'housekeeping' role of these cathepsins [1]. 
In contrast to cathepsins B, L, H and C, the recently charac-
terized cathepsins K and S exhibit a tissue-specific expression 
profile. Cathepsin K (also known as cathepsin O, 02, X and 
OC-2) has been described as a cysteine protease which plays a 
key role in bone remodeling and which is predominantly ex-
pressed in osteoclasts [2-9]. On the other hand, cathepsin S 
has been identified as the first cathepsin specifically expressed 
in lymphatic tissues [10] 
Proteases of different classes have been implicated in spe-
cific functions of the immune system. A variety of proteases 
are selectively expressed by immune cells. The best character-
ized examples are the granzymes, a family of related serine 
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proteases, which are highly expressed in CTL and NK cells. 
Granzymes have been implicated in the CTL-mediated cyto-
lytic event [11,12]. Evidence suggests that granzyme B initiates 
the apoptotic pathway of targeted cells by activation of 
CPP32 [13,14]. Cathepsin C (synonymous with dipeptidyl pep-
tidase I) is thought to activate the precursor molecules of 
granzymes by cleaving the N-terminal activation dipeptide 
[15]. 
Lysosomal cathepsins such as the aspartate protease, ca-
thepsin D, and the cysteine protease cathepsin B have been 
implicated in the degradation of exogenous antigen [16-19]. 
Processed antigen can be presented by two different types of 
MHC molecules, MHC class I and II. Cytoplasmic antigen is 
processed by the proteasome, a multicatalytic protease com-
plex, and then presented by MHC class I molecules [20,21]. 
Alternatively, exogenous antigen is taken up by endocytosis, 
transported to lysosomal-like compartments and assembled 
with MHC class II molecules. Before MHC class II molecules 
can bind to an antigenic peptide, further proteolytic process-
ing is necessary. Class II molecules are associated with the 
invariant chain li, which has to be proteolytically processed 
in the acidic lysosomal compartment. It has been shown that 
the lysosomal cysteine protease cathepsin S specifically de-
grades li and generates the CLIP peptide, a prerequisite in 
rendering class II molecules competent for binding peptides 
[22]. 
In this paper we report a novel, immune cell-specific, puta-
tive cysteine protease, cathepsin W. Cathepsin W has been 
identified from the dbEST database as a new member of the 
papain family. The protease is predominantly expressed in T-
lymphocytes. 
2. Materials and methods 
2.1. Identification of cathepsin W from the dbEST database 
To identify novel papain-related cysteine proteases, we conducted a 
search of the dbEST database using the tblastn algorithm and a con-
sensus amino acid sequence. The sequence was derived from the 
highly conserved active site region of the papain family. The query 
sequence (with the active site asparagine residue shown in bold) was 
as follows (single letter amino acid code): YWLIKNSWGTGWGEN-
GYIRI. Amongst the retrieved human sequences was one that showed 
potential similarity to the papain family of cysteine proteases (acces-
sion number R56701). Although the deposited sequence was indicated 
as having a low sequence quality, when the clone was obtained and 
sequenced, it was found to be a novel member of this family of 
proteases. 
2.2. Cloning of human cathepsin W cDNA 
The identified expressed sequence tag (accession number R56701; 
human clone number 138300) was obtained through the Lawrence 
Livermore National Laboratory and sequenced using an Applied Bio-
systems model 373A DNA sequencer. The plasmid contained an ap-
proximately 750 bp insert which included the 3' non-translating re-
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gion (nucleotides 640-1390 of the reported cDNA). The remainder of 
the sequence, including a portion of the 5' non-translating region, was 
obtained by PCR using the Pfu polymerase (Stratagene, La Jolla, CA; 
used as described by the supplier), a human placental lambda gtlO 
cDNA library as the template (Clontech, Palo Alto, CA) and primers 
corresponding to the lambda vector (5'-AGCAAGTTCAGCCTGGT-
TAAG-3') and to the cDNA clone (3'-GTAGTACGACGTCTT-
GTTGC-5'). The obtained 853-bp fragment was subcloned into a 
pBluescript II SK(+) vector (Stratagene) and sequenced. 
2.3. Preparation of RNA blots and Northern blot analysis 
Freshly isolated human blood containing an anti-coagulant was 
diluted in 1 X PBS and placed over an isotonic Percoll solution. After 
centrifugation at lOOOXg for 30 min, the mononuclear cells at the 
interface were carefully removed. The lymphocytes were then sepa-
rated into CD2, CD19, CD8, CD4 and CD14 subfractions using 
Dynabeads (Dynabeads M-450 Pan-B CD19; M-450 Pan-T CD2; 
M-450 CD4; M-450-CD8; M-450 CD14; Dynal Inc., Lake Success, 
NY). Total mRNA was isolated using a Micro RNA Isolation Kit 
from Stratagene and blotted onto a Duralon UV membrane (Strata-
gene) following formaldehyde-agarose gel electrophoresis. 
Multiple tissue (Human I, Human II, Human Immune System; 
Clontech) and lymphocyte Northern blots were hybridized for 60 
min at 68°C in ExpressHyb hybridization buffer (Clontech) containing 
an [a-32P]dCTP-labeled 500-bp fragment of either cathepsin W or 
cathepsin S. The blots were washed in 2xSSC/0.05% SDS for 60 
min at room temperature and for 60 min at 50°C in 0.1 XSSC/0.1% 
SDS. 
3. Results and discussion 
3.1. Human cathepsin W cDNA 
The cDNA of human cathepsin W encodes a 376-amino 
acid protein (Fig. 1) with a calculated molecular weight of 
42090 Da. The open reading frame starts with an ATG ini-
tiation codon at nucleotide 115 and ends at nucleotide 1302. 
Preceding the typical translation initiation sequence [23] a 
111-bp nucleotide is present. A relatively short non-translated 
3' end follows the stop codon. A typical polyadenylation site 
(AATAAA) starts 99 nucleotides after the stop codon. The 
poly A sequence begins 15 base pairs after the polyadenyla-
tion site. The total length of the sequenced cDNA of human 
cathepsin W is 1390 nucleotides. 
The open reading frame of cathepsin W contains a putative 
signal sequence, a proregion and a mature protease sequence 
typical of lysosomal cysteine proteases of the papain family. 
Using the —3, —1 rule [24] a putative cleavage site between 
the presignal and the proregion (Gly2i-Ile22) has been identi-
fied. The putative processing site between the proregion and 
the mature enzyme has been assigned to the Seri27-Vali28 
bond followed by a proline residue which is typical for cys-
teine proteases. 
Human cathepsin W contains two potential N-glycosylation 
sites, one at position —78 (N_78-R_77-S-76) in the proregion 
and one at position 78 (N78-N79-S8o) in the mature form. 
The deduced amino acid sequence of human cathepsin W 
consists of a 21-amino acid residue presignal, a 106-residue 
proregion, and a 249-residue mature form. The calculated 
molecular masses are 1865, 12060 and 26571 Da, respectively. 
Table 1 
Sequence homologies of human cathepsin W with the cathepsins L, S, K 
% to hCatW hCatL hCatS 
Preprocathepsin 27.6 29.9 
Mature cathepsin 33.6 34.1 
Proregion 22.7 20.4 
Fig. 1. Nucleotide sequence and deduced amino acid sequence of 
human cathepsm W. The putative active site residues (C153, H291 
and Asn330) are indicated by asterisks. Potential glycosylation sites 
and the polyadenylation initiation site are underlined. Arrowheads 
show the putative post-translational cleavage sites between the sig-
nal sequence and the propeptide and the propeptide and mature en-
zyme. 
3.2. Sequence similarities and differences to other human 
cysteine proteases 
To date, seven human thiol-dependent cathepsins (cathep-
sins L, K, S, B, H, O and C) have been characterized by their 
complete amino acid sequences. Multiple sequence alignments 
of these proteases clearly demonstrate that cathepsin W is a 
new member of the papain-like cysteine protease family (Fig. 
2). Table 1 shows the amino acid sequence homologies of 
human cathepsin W with the related cathepsins L, S, K, B, 
O, and H. Sequence homology is relatively low, in the range 
of 21-31%. 
All of the highly conserved residues in papain-like cysteine 
proteases were present in cathepsin W [25]. This includes the 
residues of the catalytic triad (Cys25, Hisi5g, A s n ^ ) , Glnig of 
the putative oxyanion hole, Trpi77 in the SI ' binding pocket 
as well as Gly67 and Gly68 (papain numbering). 
Besides possessing typical papain-like features, the sequence 
of human cathepsin W contains unique properties compared 
to other mammalian cathepsin sequences. The two most 
prominent differences are (1) a 21-amino acid peptide inser-
tion between the active site histidine and asparagine residue 
and (2) an 8-amino acid residue C-terminal extension. The 
peptide insertion contains a serine-glutamine-proline rich 
stretch (SSQSQPQPP). A similar Ser, Gin, Gly rich sequence 
insertion at the same site has been described for cysteine pro-
teases isolated from Dictyostelium discoideum [26]. However, 
the sequence homology to the Dictyostelium cysteine proteases 
is only 27% or less. The function of this insertion is unknown. 
The low degree of similarity to cathepsin B- and cathepsin 
L-like proteases as well as the insertion of the SPQ rich pep-
tide segment suggests that cathepsin W constitutes a subgroup 
of cathepsins distinct from the cathepsin L- and B-like sub-
groups. This assertion is also supported by a sequence com-
parison of the propeptides. Karrer et al. [27] described two 
subgroups of cysteine proteases based on a highly conserved 
motif in cathepsin L-like proteases. This so-called ERFNIN 
motif is present in cathepsin L-like but not in cathepsin B-like 
proteases. In cathepsin W, this motif is partially conserved 
(ERFNAQ, see Fig. 2). 
A further peculiarity of the sequence of cathepsin W is 
found around the active site cysteine residue. Usually, in hu-
man and other mammalian cathepsins, the third residue 
downstream from the catalytic cysteine residue is a phenyl-
alanine. In cathepsin W, however, this aromatic residue is 
replaced by a methionine followed by three alanine residues 
, H, B and O 
hCatK hCatH hCatB hCatO 
24.6 31.6 21.5 29.8 
33.5 33.6 25.4 30.4 
17.2 20.7 16.1 22.9 
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20 40 60 
tggatttccg ggcttttcta agctggcatt cacaccccga cctatcatac taagactcct 
80 100 120 
ttgttcactt tccacaacat cagagagaca ctaccaactc cagactgcac cggcatggca 
M A 
140 160 180 
ctgactgccc acccctcctg cctcctggcc ctgttggtgg caggcctagc ccaaggcatc 
L T A H P S C L L A L L V A G L A Q G A I 
200 220 240 
agaggccccc ttagggccca ggacctaggt ccccagccgc tagagctgaa agaggccttc 
R G P L R A Q D L G P Q P L E L K E A F 
260 280 300 
aagttgttcc agatccagtt caaccggagt tacctgagcc cagaagagca tgctcaccgc 
K L F Q I Q F N R S Y L S P E E H A H R 
320 340 360 
ctggacatct ttgcccacaa cctggcccag gctcagaggc tgcaggagga ggacttgggc 
L D I F A H N L A Q A Q R L Q E E D L G 
380 400 420 
acagctgaat ttggggtgac tccattcagt gacctcacag aggaggagtt tggccagctc 
T A E F G V T P F S D L T E E E F G Q L 
440 460 480 
tatggctatc ggagggcagc tggaggggtc cccagcatgg gcagagaaat aaggtctgaa 
Y G Y R R A A G G V P S M G R E I R S E 
500 520 540 
gagccagagg agtcagtacc tttcagctgt gactggcgga aggtggccgg cgccatctca 
E P E E S V A P F S C D W R K V A G A I S 
560 * 580 600 
cccatcaagg accagaaaaa ctgcaactgc tgctgggcca tggcagcggc aggcaacata 
P I K D Q K N C N C C W A M A A A G N I 
620 640 660 
aaaaccctgt ggcgcatcag tttctgggat tttgtggacg tctccgtgca ggaactgctg 
K T L W R I S F W D F V D V S V Q E L L 
680 700 720 
gactgtggcc gctgtgggga tggctgccac ggtggcttcg tctgggacgc gttcataact 
D C G R C G D G C H G G F V W D A F I T 
740 760 780 
gtcctcaaca acagcggcct ggccagtgaa aaggactacc cgttccaggg caaagtcaga 
V L N N S G L A S E K D Y P F Q G K V R 
800 820 840 
gcccacaggt gccaccccaa gaagtaccag aaggtggcct ggatccagga cttcatcatg 
A H R C H P K K Y Q K V A W I Q D F I M 
860 880 900 
ctgcagaaca acgagcacag aattgcgcag tacctggcca cttatggccc catcaccgtg 
L Q N N E H R I A Q Y L A T Y G P I T V 
920 940 960 
accatcaaca tgaagcccct tcagctatac cggaaaggtg tgatcaaggc cacacccacc 
T I N M K P L Q L Y R K G V I K A T P T 
T I N M K P L Q L Y R K G V I K A T P T 
980 * 1000 1020 
acctgtgacc cccagcttgt ggaccactct gtcctgctgg tgggttttgg cagcgtcaag 
T C D P Q L V D H S V L L V G F G S V K 
1040 1060 1080 
tcagaggagg ggatatgggc agagacagtc tcatcgcagt ctcagcctca gcctccacac 
S E E G I W A E T V S S Q S Q P Q P P H 
1100 * 1120 1140 
cccaccccat actggatcct gaagaactcc tggggggccc aatggggaga gaagggctat 
P T P Y W I L K N S W G A Q W G E K G Y 
1160 1180 1200 
ttccggctgc accgagggag caatacctgt ggcatcacca agttcccgct cactgcccgt 
F R L H R G S N T C G I T K F P L T A R 
1220 1240 1260 
gtgcagaaac cggatatgaa gccccgagtc tcctgccctc cctgaaccca cctggccccc 
V Q K P D M K P R V S C P P * 
1280 1300 1320 
tcagttctgt cctgttaggc caactgcctc cttgccagcc ccacccccag gtttgtgcca 
1340 1360 1380 
tcctcccaat ctcaatacag tctqaataaa ccaagacaag acctaaaaaa aaaaaaaaaa 
aaaaaaaaaa 
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hKatW MALTAHP9CIIATJJ/?GLA<^mGPII^IIjGPCP^^ 
hKatK M—W5-LKVIL L—PVVSFALYP-EEILDr,-H VCtWKKIHFKOflSNKvIEig^EL 
hKatS M—KR-LKVL L^-SSA\ACLHKEPILEH4J V«IWKKIYC3CQ!ifKEXNEEAVEPL 
hKatL M—NP-TLILA ART CTA.^TT,TFTK.gr , ra-n wnW!RMttKtJ«M-NEE(5*!BA 
hKatH M—Vfe-TIPUXRGRMjirVPraaAEirVNSLEKEH EKS*EKHR<TYSr—ffittHEL 
hKatO M—n/RALtVLIWriM J CR-G3TA DSSAPFT FIWPRSREREAAAFR-B3LNBH 
hKatB MW3IWASIC CLLVL—Atft R2U3FHP7S IfiL-Vte' 
ccns. M a w y E. . . r . 
bKatW DIJjAH£P^QI^EEQlH^AEF--GOTffSDLrE^^ 
hKatK -Jj£3S£JCa.SIHMLEASIjCVHIYrjJtt^^ 
hKatS -rve^rj<F^OMJEH30«EYDIi34^HLGCMraK'I^^ 
hKatL -Vl*2$MK^EIHtffiE¥KFi3<HSF^ NRKPR-R3WFCEP 
hKatH COraaWKKINfflN NOMHITO?tfJSI!ysnCFAEIKHKY-I>E^ 
hKatO PY NSIJFSHSISrAFra^SYTJ'PEEFK^Tyi^ 
hKatB -W«rajriV©Aa«JFYN\««YXj<RlCGr FICG--PKPPQR^FIED 
c a i s n hn g n. .. .m. .ee p 
1 * 
hKatW PEESWFSCEWRKVAGUSP T3^YlU&3m$$MNIKILl&asmXVDJ--SJQ?L 
hKatK WH2EAH5SvTOT!KH3 YirP^m^SXSCW^SSJ^S^EaaimfSfSUM^-SVm^ 
hKatS HKtLIDSvTWFEKS Cv*IEvKTOGS2GACT«AFSAVOtfJ^Iiai<IGKL^ 
hKatL LFYFAPHSVEWKHG WIPVKI^GQCGSCTlftFSATaaHaa^FHCIG^TSr^-sg^ 
hKatH -TGPYPPSvTWFKKS NWSPWtOG?OSCT«TSlTG?UJESVTAmTI3lCSL-^H2(X 
hKatO PM/SLPLRFEWPDH2 WV^mQfMSS^m^^M^JES^Km^^JEDLr-S^y 
hKatB LK--LEASFmHE(34PQCPTIKE:rfiIjQG3^^ 
ccns P.svEwR.k v..\fc.Qg.OgsCWafs.. .gale t L . s . q . l 
hKatW LDCGR CGDG^H3Q?\WI3^TvlMEG-IA£EKDY PF QG 
hKatK VDCVSE—^^ra3aMIlMQW!3<^p.G-IDSEmY PV 
hKatS VirSIEKa3Ka3CCIMrTJ^YIICtKG-inSnASY PY 
hKatL \mZ3GB2-<S^n3G3iMJimiyJQ^CG-WSEESY PV 
hKatH VrX^KPH^KCEQSCiPS^FEYIIJYI^G-IMiErY Pi 
hKatO IDCS Y^TOra30STlNSlAIJMNR4^^«LVKE6D IF 
hKatB LT033S>*a3r><rNX3ra«7WF-Wiraa 
ccns. .<£ n.OCrGG... . a . . y . . .n.G. . . s . . . y Py 
hKatW -KVRAHKH—PKKYaCV7^Q--DFrMi£NN mCOQiIATiGPTFVFim--K£lJ3jY 
hKatK -V3g=ISCM--YNPIT2™HIR--GYREIP B3tWKRA\mK3PVSVAmASljrSFa;'Y 
hKatS -KAMDyCQ—YDSKYEMICS—KVTELP YGRED J^<EVMi<GPVSW3VnARHPa;TLY 
hKatL -EATEESCK—TOHCYS\ffiN3r--G£Vnr.P H2-EKMMKAmTVGPISVATrj«3ESlFY 
hKatH -Q3KDGWX—H2K3K«GFvT<--rMOTT--:n^ 
hKatO -KAQSiaGi-YF3G3H3CTSIK-H3YSffifr>-FS^ 
hKatB GB3OTPXCSKICEK3YSPTmp<mGYNSYSv'^  
ccns C E a .a . .gP f ..Y 
* * 
hKatW RK3vlK^TPTra3PQLVTJISVlXVa;XSvKSEB3IWAFnVS3CS(pyPH^ 
hKatK SH3VYYDESC--NaMJ«AVLAVGYG IQIQaGWIIIWSWG 
hKatS R33VYY-EPS--ClCiNWHGVLWGYG EUGKEYWLVmSWG 
hKatL KE3IYFEPDC—SSEEMEHGVLWGYC? ESTESIMtfYWLVIWSWG 
hKatH RIGIYSSTSCHJCTPDKOTHAVLAVGYG EKN3TPYWIVMISWG 
hKatf) LG3I-IQH1C—S33EANHAVLITGFD KTGSTPYWIVFNSWG 
hKatB KSGVYCHvT GEMM33IAIRILGW3/ ^EN3IPYWLV7NSWN 
ccns y H.vlv.G.g yW.-\&N3Wj 
hKatW A(^ GEKGYFRIHR3S-NTCGTrK FPLTARW2KPIMKPRVSCPP 376 
hKatK EtWG^GYTIM«JKNM\CGIAN--LASFP-K M 329 
hKatS H^FGEH3YIIWAR^KG^DCGIAS--FPSYP-E 1 331 
hKatL ES»GM3GYVTOftKrjTOH03IAS--AASYP-T V 333 
hKatH r^GMJGYFLIFJGK-M«iaAA-<aSYP-IP LV 335 
hKatO SSWGVDGYAHWbES-WG31AD--SvS SI EV 322 
hKatB TTJIGn^STKILGSOrfflaSIESEvV^IPRrTQYW-EKI 339 
ccns. . .wG. .Gy n.CGia p 
63 
48 
50 
50 
55 
51 
32 
123 
110 
110 
109 
112 
104 
77 
181 
167 
167 
166 
169 
160 
138 
219 
203 
197 
204 
207 
197 
199 
272 
259 
262 
259 
234 
229 
262 
334 
299 
301 
303 
304 
293 
301 
Fig. 2. Multiple amino acid alignement of human cathepsin W with human cathepsins K, S, L, H, O and B. *, active site residues; conserved 
residues of the ERFNIN motif in the propeptides are underlined. Amino acids identical in all seven proteases are assigned as upper case letters 
in the consensus sequence, and amino acids identical in five out of seven are assigned in lower case letters. Gaps are indicated by hyphens. 
Numbers indicate the position of the last amino acid in each line and arrowheads show the putative post-translational cleavage sites. Sequence 
informations have been taken from the following references: hCatK [5]; hCatS [31]; hCatL [32]; hCatH [33]; hCatO [34]; hCatB [35]. 
(CWAMAAA). A similar sequence in this region has also 
been described for two papain-like sequences from Caenorhab-
ditis elegans [28]. In other human cathepsins, the neighboring 
residue upstream from the active site Cys25 is either a serine, 
alanine or glycine. In this position, cathepsin W contains a 
second cysteine residue. Since the mature part of the protease 
contains 11 cysteine residue it may form up to 5 disulfide 
bridges. 
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Fig. 3. Northern blot analysis of human cathepsins W and S in human tissues and tumor cell lines. Nitrocellulose blots were hybridized with 
32P-labeled probes of human cathepsins W and S. A: Cathepsin W; B: actin was used as control probe; C: cathepsin S. The additional signal 
at approximately 4.4 kb may represent an alternatively spliced transcript of cathepsin S. See also Figs. 4 and 5. 
3.3. Tissue distribution of human cathepsin W 
Cathepsin W was detected exclusively in tissues of the im-
mune system by Northern blot analysis. The approximate size 
of the cathepsin W mRNA on the Northern blots is 1.45 kb 
which closely matches the size of the sequenced cDNA (1.38 
kb). High mRNA levels were observed in peripheral blood, 
spleen and lymph nodes, medium levels in bone marrow and 
appendix and low to very low levels in thymus (Figs. 3 and 4). 
Human cathepsin S, which has been previously described as a 
lymphoid tissue-specific cathepsin, is characterized by an al-
most identical expression pattern (Figs. 3 and 4). In addition, 
cathepsin S is also expressed in lung, liver and placenta. Im-
258 C. Linnevers et al.lFEBS Letters 405 (1997) 253-259 
munohistochemical studies have assigned the expression of 
cathepsin S to alveolar macrophages in lung tissue [29] and 
to Kupffer cells in liver tissue (D. Bromme, unpublished re-
sults). No detectable levels of cathepsin W expression could be 
observed in various tumor cell lines whereas cathepsin S dis-
played expression in cell lines such as HL-60, HeLaS3, Raji, 
SW480 and A549 (Fig. 3). 
In order to distinguish between the expression patterns of 
cathepsins W and S, a differential lymphocyte Northern blot 
was prepared. Cathepsin W was detected specifically in the T-
cell population, and in particular, at very high levels in cyto-
toxic T-cells (CD8+). A low signal was also observed in CD4+ 
T-cells (Fig. 5). 
In contrast, cathepsin S was almost exclusively detected in 
the monocytic cell population (CD 14) and at very low levels 
in B-cells. Monocyte-derived macrophages and B-lymphocytes 
Fig. 5. Northern blot analysis of human cathepsins W and S in hu-
man lymphocytes. A: Cathepsin W; B: cathepsin S; C: GDPH was 
used as control probe. 
Fig. 4. Northern blot analysis of human cathepsin W and S in hu-
man immune tissues. A: Cathepsin W; B: cathepsin S; C: actin 
was used as control probe, pbl, peripheral blood leukocytes. 
are known to be involved in MHC class II antigen presenta-
tion. It has been demonstrated that cathepsin S is directly 
involved in MHC class II antigen presentation by specifically 
cleaving the invariant chain [22]. 
It can be assumed that the expression of cathepsins W and 
S in spleen, lymph nodes, appendix and bone marrow is at-
tributed to resident monocytes and CD8+ cells in these or-
gans. 
Interestingly, cathepsin W is only very weakly expressed in 
the thymus. Since the vast majority of thymic T cells are 
represented by immature CD4+8+ thymocytes and since ca-
thepsin W is almost exclusively expressed in CD8+ cells, it can 
be concluded that the induction of cathepsin W is in some 
way coupled with the process of thymocyte selection in the 
thymus. Furthermore, the specific expression of cathepsin W 
in CD8+ cells suggests a specific function of this protease in 
the cytolytic activity of cytotoxic T cells. So far, only the 
granzymes, a subclass of serine proteases, have been described 
as specific to CTL-lymphocytes. 
In conclusion, cathepsin W is the third example of a cell 
type-specific cathepsin of the papain family. So far only ca-
thepsin S has been described as a monocyte/macrophage-spe-
C. Linnevers et al.lFEBS Letters 405 (1997) 253-259 259 
cific protease [10,30] and cathepsin K as an osteoclast-specific 
cathepsin [2]. The cell-specific expression of these proteases 
raises the questions: (1) D o other cell- and tissue-specific ca-
thepsins exist? and 2) Wha t makes them functionally different 
from the ubiquitously expressed cathepsins B, L and H ? 
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